Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

被引：0
|
作者：
Michael A Postow
Diana M Cardona
Janis M Taube
Robert A Anders
Clive R Taylor
Jedd D Wolchok
Margaret K Callahan
Michael A Curran
Alexander M Lesokhin
Joseph F Grosso
Christine E Horak
John Cogswell
Jason S Simon
Ashok K Gupta
Mario Sznol
机构：
[1] Memorial Sloan-Kettering Cancer Center,Keck School of Medicine
[2] Duke University School of Medicine,undefined
[3] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[4] University of Southern California,undefined
[5] Bristol-Myers Squibb,undefined
[6] Yale University School of Medicine and Yale Cancer Center,undefined
来源：
Journal of Translational Medicine | / 12卷 / Suppl 1期
关键词：
Ipilimumab; Tumor Infiltrate Lymphocyte; Advanced Melanoma; Myeloid Derive Suppressor Cell; Absolute Lymphocyte Count;
D O I：
10.1186/1479-5876-12-S1-O8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 159 - 159
  • [32] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538)
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
    Segal, Neil Howard
    Hodi, F. Stephen
    Sanborn, Rachel E.
    Gajewski, Thomas
    Wolchok, Jedd D.
    Urba, Walter John
    Fox, Bernard A.
    Topallan, Suzanne Louise
    Pardoll, Drew M.
    Kollia, Georgia
    McDonald, Dan
    Kim, Su Young
    Sharfman, William Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
    Sangro, Bruno
    Crocenzi, Todd S.
    Welling, Theodore Hobart
    Inarrairaegui, Mercedes
    Prieto, Jesus
    Fuertes, Carmen
    Delanty, Laurie
    Feely, William
    Anderson, Jeffrey
    Grasela, Dennis M.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Sznol, Mario
    Kluger, Harriet M.
    Hodi, F. Stephen
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [36] A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
    Motzer, R. J.
    Bono, P.
    Tomita, Y.
    Ravaud, A.
    Waxman, I.
    Gore, M. E.
    BJU INTERNATIONAL, 2013, 112 : 10 - 10
  • [37] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
    Gettinger, Scott
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
  • [38] Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
    Rizvi, Naiyer A.
    Chow, Laura Quan Man
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott Joseph
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca Suk
    Carvajal, Richard D.
    Jackman, David Michael
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne Louise
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher
    Kollia, Georgia
    Gupta, Ashok Kumar
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Brahmer, J. R.
    Gettinger, S.
    Chow, L. Q.
    Juergens, R.
    Shepherd, F. A.
    Laurie, S. A.
    Gerber, D. E.
    Goldman, J.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Borghaei, H.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S2
12345